Loading insider details...
Beta
Latest Form 4 (Oct 3, 2026): Exercise/Conversion of 17,500 SYRE shares, $253.8K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 3, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 17,500 | $253.8K |
| Sep 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 7,500 | $108.8K |
| Aug 6, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 7,500 | $108.8K |
| Jul 3, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 7,500 | $108.8K |
| Jun 27, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 15,000 | $217.5K |
| Jun 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 7,500 | $108.8K |
| May 2, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 12,500 | $181.3K |
| Apr 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 7,500 | $108.8K |
| Mar 4, 2026 | Spyre Therapeutics, Inc. (SYRE) | Exercise/Conversion | 2,500 | $36.3K |
| Jan 14, 2026 | Spyre Therapeutics, Inc. (SYRE) | Grant/Award | 140,000 | n/a |